-
公开(公告)号：US20230114718A1
公开(公告)日：2023-04-13
申请号：US17688908
申请日：2022-03-08
Applicant: AbbVie Inc.
Inventor： Erwin R. Boghaert , Milan Bruncko , Andrew S. Judd , Andrew C. Phillips , Andrew J. Souers
IPC: C07K16/28 , A61K47/68 , A61K47/65 , A61P35/00 , A61K31/5377
Abstract: The invention relates to anti-Epidermal Growth Factor Receptor (EGFR) antibody drug conjugates (ADCs) which inhibit Bcl-xL, including compositions and methods of using said ADCs.
-
公开(公告)号：US20220226494A1
公开(公告)日：2022-07-21
申请号：US17580134
申请日：2022-01-20
Applicant: AbbVie Inc.
Inventor： Erwin R. Boghaert , Milan Bruncko , Andrew C. Phillips , Andrew J. Souers , Kamel Izeradjene , John E. Harlan
Abstract: The present disclosure relates to anti-Epidermal Growth Factor Receptor (EGFR) antibody drug conjugates (ADCs) which inhibit Bcl-xL, including compositions and methods using such ADCs, and methods for making such ADCs.
-
53.发明申请公开(公告)号：US20200246460A1
公开(公告)日：2020-08-06
申请号：US16563507
申请日：2019-09-06
Applicant: AbbVie Inc.
Inventor： Scott L. Ackler , Nathan B. Bennett , Erwin R. Boghaert , Steve C. Cullen , George Doherty , Robin R. Frey , Anthony R. Haight , Andrew S. Judd , Aaron R. Kunzer , Violeta L. Marin , Xiaoqiang Shen , Xiaohong Song , Andrew J. Souers , Gerard M. Sullivan , Zhi-Fu Tao , Xilu Wang , Dennie S. Welch , Michael D. Wendt
IPC: A61K45/06 , A61K31/4725 , A61K31/4985 , A61K31/498 , A61K47/68 , A61K31/538 , A61K31/4709 , C07D417/14 , C07D487/04 , C07D513/04
Abstract: The present disclosure concerns Bcl-xL inhibitors having low cell permeability, antibody drug conjugates (ADCs) comprising the inhibitors, synthons useful for synthesizing the ADCs, compositions comprising the inhibitors or ADCs, and various methods of using the inhibitors and ADCs.
-
54.发明申请公开(公告)号：US20190142941A1
公开(公告)日：2019-05-16
申请号：US16240544
申请日：2019-01-04
Applicant: AbbVie Inc.
Inventor： Scott L. Ackler , Nathan B. Bennett , Erwin R. Boghaert , Steve C. Cullen , George Doherty , Robin R. Frey , Anthony R. Haight , Andrew S. Judd , Aaron R. Kunzer , Violeta L. Marin , Xiaoqiang Shen , Xiaohong Song , Andrew J. Souers , Gerard M. Sullivan , Zhi-Fu Tao , Xilu Wang , Dennie S. Welch , Michael D. Wendt
IPC: A61K45/06 , A61K47/68 , C07D513/04 , C07D487/04 , A61K31/538 , A61K31/4709 , A61K31/4725 , A61K31/498 , A61K31/4985 , C07D417/14
Abstract: The present disclosure concerns Bcl-xL inhibitors having low cell permeability, antibody drug conjugates (ADCs) comprising the inhibitors, synthons useful for synthesizing the ADCs, compositions comprising the inhibitors or ADCs, and various methods of using the inhibitors and ADCs.
-
公开(公告)号：US20170355769A1
公开(公告)日：2017-12-14
申请号：US15616901
申请日：2017-06-07
Applicant: AbbVie Inc.
Inventor： Lorenzo Benatuil , Milan Bruncko , Debra Chao , Kamel Izeradjene , Andrew S. Judd , Andrew C. Phillips , Andrew J. Souers , Archana Thakur
Abstract: The invention relates to B7 homology 3 protein (B7-H3) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.
-
Patent Agency Ranking
56.发明申请BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same 审中-公开具有低细胞渗透性的BCL-XL抑制性化合物和包括其的抗体药物偶联物公开(公告)号：US20160339117A1
公开(公告)日：2016-11-24
申请号：US14963506
申请日：2015-12-09
Applicant: AbbVie Inc.
Inventor： Scott L. Ackler , Nathan B. Bennett , Erwin R. Boghaert , Steve C. Cullen , George Doherty , Robin R. Frey , Anthony R. Haight , Andrew S. Judd , Aaron R. Kunzer , Violeta L. Marin , Xiaoqiang Shen , Xiaohong Song , Andrew J. Souers , Gerard M. Sullivan , Zhi-Fu Tao , Xilu Wang , Dennie S. Welch , Michael D. Wendt
IPC: A61K47/48 , C07D417/14 , A61K31/4725 , C07D487/04 , A61K31/538 , A61K31/498 , A61K31/4709 , A61K31/4985 , A61K45/06 , C07D513/04
CPC classification number: A61K45/06 , A61K31/4709 , A61K31/4725 , A61K31/498 , A61K31/4985 , A61K31/538 , A61K47/6803 , A61K47/6849 , A61K47/6851 , A61K47/6883 , A61K47/6889 , C07D417/14 , C07D487/04 , C07D513/04
Abstract: The present disclosure concerns Bcl-xL inhibitors having low cell permeability, antibody drug conjugates (ADCs) comprising the inhibitors, synthons useful for synthesizing the ADCs, compositions comprising the inhibitors or ADCs, and various methods of using the inhibitors and ADCs.
Abstract translation: 本公开涉及具有低细胞通透性的Bcl-xL抑制剂，包含抑制剂的抗体药物偶联物（ADC），可用于合成ADC的合成物，包含抑制剂或ADC的组合物，以及使用抑制剂和ADC的各种方法。
-
57.发明申请APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES 审中-公开用于治疗癌症和免疫和自发性疾病的疫苗诱导剂公开(公告)号：US20150329541A1
公开(公告)日：2015-11-19
申请号：US14694965
申请日：2015-04-23
Inventor： Milan Bruncko , Hong Ding , George A. Doherty , Steven W. Elmore , Lisa A. Hasvold , Laura Hexamer , Aaron R. Kunzer , Xiaohong Song , Andrew J. Souers , Gerard M. Sullivan , Zhi-Fu Tao , Gary T. Wang , Le Wang , Xilu Wang , Michael D. Wendt , Robert Mantei , Todd M. Hansen
IPC: C07D471/04
CPC classification number: C07D401/12 , A61K31/496 , C07D209/82 , C07D401/14 , C07D403/12 , C07D471/04 , C07D519/00 , Y02A50/463
Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.
Abstract translation: 公开了抑制抗凋亡Bcl-2蛋白活性的化合物，含有化合物的组合物和治疗疾病的方法，其中表达抗凋亡Bcl-2蛋白。
-
58.发明授权公开(公告)号：US09174982B2
公开(公告)日：2015-11-03
申请号：US14038304
申请日：2013-09-26
Inventor： Milan Bruncko , Hong Ding , George A. Doherty , Steven W. Elmore , Lisa A. Hasvold , Laura Hexamer , Aaron R. Kunzer , Xiaohong Song , Andrew J. Souers , Gerard M. Sullivan , Zhi-Fu Tao , Gary T. Wang , Le Wang , Xilu Wang , Michael D. Wendt , Robert A. Mantei , Todd M. Hansen
IPC: C07D209/82 , C07D403/12 , C07D401/14 , C07D471/04 , C07D519/00 , A61K31/496
CPC classification number: C07D401/12 , A61K31/496 , C07D209/82 , C07D401/14 , C07D403/12 , C07D471/04 , C07D519/00 , Y02A50/463
Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.
-
59.发明授权Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases 有权Bcl-2选择性细胞凋亡诱导剂用于治疗癌症和免疫疾病公开(公告)号：US09125913B2
公开(公告)日：2015-09-08
申请号：US14058159
申请日：2013-10-18
Applicant: AbbVie Inc.
Inventor： Milan Bruncko , Hong Ding , George A. Doherty , Steven W. Elmore , Lisa Hasvold , Laura A. Hexamer , Aaron R. Kunzer , Robert A. Mantei , William J. McClellan , Chang H. Park , Cheol-Min Park , Andrew M. Petros , Xiaohong Song , Andrew J. Souers , Gerard M. Sullivan , Zhi-Fu Tao , Gary T. Wang , Le Wang , Xilu Wang , Michael D. Wendt
IPC: A61K31/495 , A61K31/496 , A61K31/501 , A61K31/5377 , C07D209/32 , C07D211/96 , C07D213/64 , C07D215/20 , C07D217/16 , C07D231/56 , C07D235/26 , C07D249/04 , C07D295/125 , C07D295/14 , C07D309/14 , C07D401/12 , C07D405/12 , C07D405/14 , C07D417/12 , C07D471/04 , A61K31/407 , A61K45/06 , C07D241/04 , C07D401/06 , C07D403/06 , C07D405/06 , C07D413/06 , C07D487/04
CPC classification number: C07D401/12 , A61K31/407 , A61K31/495 , A61K31/496 , A61K31/501 , A61K31/5377 , A61K45/06 , C07D209/08 , C07D209/32 , C07D211/58 , C07D211/96 , C07D213/64 , C07D215/20 , C07D217/16 , C07D231/56 , C07D235/26 , C07D241/04 , C07D249/04 , C07D295/125 , C07D295/14 , C07D295/155 , C07D309/04 , C07D309/14 , C07D401/06 , C07D403/06 , C07D405/06 , C07D405/12 , C07D405/14 , C07D413/06 , C07D417/12 , C07D471/04 , C07D487/04
Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 or Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which are expressed anti-apoptotic Bcl-2 protein.
Abstract translation: 公开了抑制抗凋亡Bcl-2或Bcl-xL蛋白的活性的化合物，含有该化合物的组合物和治疗疾病的方法，其中表达抗凋亡Bcl-2蛋白。
-
![Pyrrolo[2,3-B]pyridine CDK9 kinase inhibitors](/abs-image/US/2015/07/07/US09073922B2/abs.jpg.150x150.jpg)
公开(公告)号：US09073922B2
公开(公告)日：2015-07-07
申请号：US14207886
申请日：2014-03-13
Applicant: AbbVie Inc.
Inventor： Jianchun Gong , Zhi-Fu Tao , Thomas D. Penning , Andrew J. Souers , Yunsong Tong , Guidong Zhu
IPC: C07D401/10 , A61K31/437 , A61K31/4353 , C07D471/04 , A61K31/497 , A61K31/5377
CPC classification number: C07D471/04 , A61K31/437 , A61K31/444 , A61K31/4545 , A61K31/497 , A61K31/5377 , A61K45/06 , A61K2300/00
Abstract: Disclosed are compounds of Formula (IIIa), wherein R1, R2, R3, X1, X2, X3, X4, X5, have any of the values defined therefore in the specification, and pharmaceutically acceptable salts thereof. The compounds may be used as agents in the treatment of diseases, including cancer. Also provided are pharmaceutical compositions comprising one or more compounds of Formula (IIIa).
Abstract translation: 公开了式（IIIa）的化合物，其中R 1，R 2，R 3，X 1，X 2，X 3，X 4，X 5具有本说明书中定义的任何值及其药学上可接受的盐。 这些化合物可以用作治疗包括癌症在内的疾病的药剂。 还提供了包含一种或多种式（IIIa）化合物的药物组合物。
-
-
-
-
-
-
-
-
-
Search Results
89
records
(took 0.106 seconds)
